Download PDF
Dtsch Med Wochenschr 2015; 140(10): 750-755
DOI: 10.1055/s-0041-102000
Fachwissen
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Vorhofflimmern: Wie effektiv und sicher sind die direkten oralen Antikoagulanzien zur Prävention von Schlaganfällen?

Stroke prevention with direct oral anticoagulants in patients with non-valvular atrial fibrillation
Stefan H. Hohnloser
1   Klinische Elektrophysiologie, Med. Klinik III, Kardiologie, J. W. Goethe Universität Frankfurt
,
Máté Vámos
1   Klinische Elektrophysiologie, Med. Klinik III, Kardiologie, J. W. Goethe Universität Frankfurt
,
Hans-Christoph Diener
2   Universitätsklinik für Neurologie, Essen
› Author Affiliations
Further Information

Publication History

Publication Date:
13 May 2015 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die Entwicklung der direkten oralen Antikoagulantien stellt einen der größten medizinischen Fortschritte der letzten 10 Jahre dar. Im Vergleich zu den Vitamin K Antagonisten sind diese Medikamente (Dabigatran als Thrombin-Inhibitor, Rivaroxaban, Apixaban und Edoxaban als Faktor Xa Hemmer) aufgrund ihrer pharmakologischen Eigenschaften ungleich einfacher anzuwenden. Alle direkten oralen Antikoagulantien weisen eine bessere Wirksamkeit und eine höhere Sicherheit als die Vitamin K Antagonisten auf, wie in den entsprechenden Zulassungsstudien an mehr als 71 000 Patienten gezeigt worden ist. Insbesondere die viel geringere Häufigkeit intrakranieller Blutungen machen die DOACs zu Medikamenten der ersten Wahl für die primäre und sekundäre Schlaganfallprävention bei nicht-valvulärem Vorhofflimmern.

Abstract

The development of the direct oral anticoagulants (DOACs) represents one of the major breakthroughs in modern medicine over the last decade. Compared to vitamin K antagonists, all DOACs (dabigatran as a thrombin-Inhibitor, rivaroxaban, apixaban and edoxaban as factor Xa inhibitors) are much easier to handle due to their pharmacological properties. All DOACS are more efficacious and safer as vitamin K antagonists as demonstrated in the pivotal studies in more than 71 000 patients. Particularly the much lower risk of intracerebral bleeding complications is the reason why the DOACs should be preferred over vitamin K antagonists in patients with non-valvular atrial fibrillation.

Schlüsselwörter

Nicht-valvuläres Vorhofflimmern - Schlaganfall-Prävention - direkte orale Antikoagulantien

Keywords

Non-valvular atrial fibrillation - stroke prevention - direct oral anticoagulants
 

  • Literatur

  • 1 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991; 22: 983-988
    CrossrefPubMedSearch in Google Scholar
  • 2 Hohnloser SH, Pajitnev D, Pogue J et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50: 2156-161
    CrossrefPubMedSearch in Google Scholar
  • 3 Marini C, De Santis F, Sacco S et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-1119
    CrossrefPubMedSearch in Google Scholar
  • 4 Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology 2003; 22: 118-123
    CrossrefPubMedSearch in Google Scholar
  • 5 Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe. Stroke 2001; 32: 392-398
    CrossrefPubMedSearch in Google Scholar
  • 6 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69: 546-554
    CrossrefPubMedSearch in Google Scholar
  • 7 Hart R, Benavente O, McBride R, Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501
    PubMedSearch in Google Scholar
  • 8 Mant J, Hobbs FDR, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503
    CrossrefPubMedSearch in Google Scholar
  • 9 Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europ Heart J 2012; 33: 2719-2749
    CrossrefPubMedSearch in Google Scholar
  • 10 Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 160S-198S
    CrossrefPubMedSearch in Google Scholar
  • 11 Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29: 155-165
    PubMedSearch in Google Scholar
  • 12 Hylek E, Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902
    CrossrefPubMedSearch in Google Scholar
  • 13 Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117: 493-499
    CrossrefPubMedSearch in Google Scholar
  • 14 Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401
    CrossrefPubMedSearch in Google Scholar
  • 15 Ogilvie IM, Newton N, Welner SA et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638-645
    CrossrefPubMedSearch in Google Scholar
  • 16 Kakkar AK, Mueller I, Bassandet JP et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS One 2013; 8: e63479
    CrossrefPubMedSearch in Google Scholar
  • 17 Meinertz T, Kirch W, Rosin L et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100: 897-905
    CrossrefPubMedSearch in Google Scholar
  • 18 Baker JWL, Cios DA, Sander SD, Coleman CI. Meta-Analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 2344-2252
    PubMedSearch in Google Scholar
  • 19 Dlott JS, George RA, Huang X et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014; 129: 1407-1414
    CrossrefPubMedSearch in Google Scholar
  • 20 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedSearch in Google Scholar
  • 21 Granger C, Alexander J, McMurray J et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedSearch in Google Scholar
  • 22 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedSearch in Google Scholar
  • 23 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    PubMedSearch in Google Scholar
  • 24 Ruff TR, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
    CrossrefPubMedSearch in Google Scholar
  • 25 Hylek E, D’Antonio J, Evans-Molina C et al. Translating the results of randomized trials into clinical practice. Stroke 2006; 37: 1075-1080
    CrossrefPubMedSearch in Google Scholar
  • 26 Lip GYH, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients. Thromb Haemost 2011; 106: 997-911
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163
    CrossrefPubMedSearch in Google Scholar
  • 28 Hankey GH, Patel MR, Stevens SR et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
    CrossrefPubMedSearch in Google Scholar
  • 29 Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11: 503-511
    CrossrefPubMedSearch in Google Scholar
  • 30 Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized evaluation of long-term anticoagulation therapy) trial. Circulation 2012; 125: 669-676
    CrossrefPubMedSearch in Google Scholar
  • 31 Dans AL, Connolly SJ, Wallentin L et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY®) Trial. Circulation 2013; 127: 634-640
    CrossrefPubMedSearch in Google Scholar
  • 32 Bahit MC, Lopes RD, Wojdyla DM et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial. Int J Cardiol 2013; 170: 215-220
    CrossrefPubMedSearch in Google Scholar
  • 33 Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban versus Vitamin K Antagonists for Cardioversion in Atrial Fibrillation. Eur Heart J 2014; 35: 3346-3355
    CrossrefPubMedSearch in Google Scholar
  • 34 Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation. An analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136
    CrossrefPubMedSearch in Google Scholar
  • 35 Flaker G, Lopes RD, Al-Khatib SM et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation. Insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 63: 1082-1087
    PubMedSearch in Google Scholar
  • 36 Xian Y, Liang L, Smith EE et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012; 307: 2600-2608
    Search in Google Scholar
  • 37 Diener HC, Foerch C, Riess H et al. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol 2013; 12: 677-688
    CrossrefPubMedSearch in Google Scholar
  • 38 Heidbuchel H, Verhamme P, Alings M et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651
    CrossrefPubMedSearch in Google Scholar
  • 39 Hylek EM, Held C, Alexander JH et al. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin in the ARISTOTLE Trial: Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63: 2141-2147
    CrossrefPubMedSearch in Google Scholar
  • 40 Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural Characterization. Blood 2013; 121: 3554-3562
    CrossrefPubMedSearch in Google Scholar